Early last year, Moderna launched a clinical trial for another mRNA “vaccine,” in light of what a smashing success their COVID-19 shots were (at inducing myocarditis in children and generating record profit).
Via UMass Chan Medical School, January 2022:
UMass Chan Medical School researchers are embarking on a clinical trial of an mRNA vaccine by Moderna against the Epstein-Barr virus (EBV), a common cause of infectious mononucleosis. EBV has also been associated with several autoimmune disorders and has been implicated in the development of several cancers, including Burkitt and Hodgkin’s lymphomas.
The study, called the Eclipse Trial, is a randomized, observer-blind, placebo-controlled, dose-ranging Phase I clinical trial in 18- to 30-year-old healthy adults. Study participants will be randomly assigned to one of four arms: one for each of three doses of the investigational vaccine and one placebo.
The investigational vaccine targets four glycoprotein antigens on the virus particle, using the same type of mRNA vaccine platform used for mRNA COVID vaccines.
Let’s get out of the way upfront, which should be emphasized anyone we are discussing these…
Read the full article here